Antacids Market by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents), Formulation (Liquid, Powder, Tablet), Indication, Distribution Channel - Global Forecast 2024-2030
Antacids Market by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents), Formulation (Liquid, Powder, Tablet), Indication, Distribution Channel - Global Forecast 2024-2030
The Antacids Market size was estimated at USD 6.85 billion in 2023 and expected to reach USD 7.24 billion in 2024, at a CAGR 5.81% to reach USD 10.18 billion by 2030.
Antacid is a type of medication that is used to neutralize stomach acidity and alleviate symptoms associated with excess gastric acid. These include conditions such as heartburn, indigestion, and stomach upset, providing relief by increasing the pH balance in the stomach. The antacid products are available in various forms, including tablets, liquids, and powders to relieve symptoms associated with gastroesophageal reflux disease (GERD), heartburn, and peptic ulcers. The rising prevalence of GERD, heartburn, and other gastric ailments globally is driving the need for antacid products. Modern dietary habits and lifestyles contribute to increased incidences of acidity and related disorders, further propelling the demand for antacids. Continuous research and development aimed at enhancing product efficacy and reducing side effects positively impact market growth. However, stringent regulations regarding the approval and marketing of antacid products can delay product launches, hampering market growth. The availability of alternative therapies and treatments for acid-related disorders poses a significant challenge for market growth. Moreover, ongoing research into natural and organic ingredients can effectively relieve acidity and related conditions, creating opportunities for market growth. Ongoing innovation in drug delivery technologies to improve the efficacy and duration of action of antacid products, generating growth potential in the market.
Regional Insights
In the Americas region, the antacids market is driven by a high prevalence of gastroesophageal reflux disease (GERD) and stress-induced gastritis, amongst other digestive disorders. Consumer preferences lean toward fast-acting, flavored, and chewable forms in major countries such as the United States and Canada. The EMEA region presents a diverse landscape for antacids as the EU countries prioritize medically proven, prescription-based treatments due to stringent regulations. The EMEA market is characterized by a strong presence of global pharmaceutical brands and a growing interest in antacids that offer additional health benefits, such as probiotics. The antacids market in the Middle East and Africa is expanding, driven by lifestyle diseases and an increasing preference for self-medication. Moreover, in the APAC region, the burgeoning middle-class population and increased healthcare spending in China and India are expanding the adoption of antacids in the region. The rising aging population in Japan and a strong focus on preventive healthcare bolster the use of antacids in the APAC region. The domestic antacids market in India is propelled by lifestyle changes, increased fast food consumption, and rising awareness of over-the-counter (OTC) remedies.
Market Insights
Market Dynamics
The market dynamics represent an ever-changing landscape of the Antacids Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
Growing population suffering from gastroesophageal reflux disease
Government initiatives and investments for domestic drug manufacturing worldwide
Market Restraints
Availability of home remedies and other alternatives for acidity-related issues
Market Opportunities
Development of more instantly effective and long-lasting antacids
Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
Market Challenges
Drug recall and contamination issues associated with the antacids
Market Segmentation Analysis
Drug Class: Increasing preference for acid neutralizers for improved therapeutic action
Indication: Expanding need for antacids for the management of gastroesophageal reflux disease for reducing the acid’s ability to damage the esophageal lining.
Formulation: Rising preference for liquid antacid due to their already dissolved state, facilitating quicker relief from symptoms
Distribution Channel: Growing availability of antacids across retail pharmacies that provide instant access to antacids without the need for a prescription
Market Disruption Analysis
Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antacids Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antacids Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
TUMS partners with DraftKings to introduce an innovative platform, TUMS Prop Bites. This unique initiative creates awareness about making free food predictions by offering a chance to compare their selections with others nationwide. The brand's antacid tablets and chews are crafted to immediately relieve heartburn. These chewable solutions address symptoms such as heartburn, acid indigestion, sour stomach, and discomfort.
Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio
Dexcel Pharma Ltd. announced its strategic acquisition of eight reputable over-the-counter (OTC) brands to diversify and strengthen its consumer healthcare offerings. The enhanced portfolio features well-known products such as EarCalm Spray, Sominex for sleep assistance, Wind-Eze as an antacid, Bisodol for indigestion relief, Cymex for cold sore treatment, Liberize for erectile dysfunction, Yeast Vite supplements, and MacKenzies Smelling Salts for catarrh and colds.
Camber Pharmaceuticals Launches Generic Wellbutrin SR
Camber Pharmaceuticals expanded its product line by introducing Famotidine Powder for oral suspension, USP, a treatment developed to address various gastrointestinal conditions. Suitable for adults, this formulation effectively treats active duodenal and gastric ulcers, relieving the symptoms of non-erosive gastroesophageal reflux disease (GERD).
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antacids Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Antacids Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aero Healthcare AU Pty Ltd, Alcon Industries, Alkem Laboratories Ltd., Allegiant Health, AstraZeneca plc, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals, Inc., Cipla Limited, Daiichi Sankyo Company Limited, Dexcel Ltd., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Haleon PLC, Imerys S.A., J. B. Chemicals & Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Magmit Pharmaceutical Co., Ltd., Mankind Pharma Ltd., Marksans Pharma, Nestlé S.A., Novartis AG, Perrigo Company plc, Pfizer Inc., Raritan Pharmaceuticals, Inc., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Swiss Chem Healthcare by Swastik Lifesciences, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals, Wonderbelly, and Zoic Pharmaceuticals Pvt. Ltd..
Market Segmentation & Coverage
This research report categorizes the Antacids Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug Class
Acid Neutralizers
Aluminum Hydroxide
Calcium Carbonate
Magnesium Hydroxide
Sodium Bicarbonate
H2 Antagonist
Promotility Agents
Proton Pump Inhibitor
Formulation
Liquid
Powder
Tablet
Indication
Gastroesophageal Reflux Disease
Indigestion/Dyspepsia
Peptic Ulcer Disease
Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing population suffering from gastroesophageal reflux disease
5.1.1.2. Government initiatives and investments for domestic drug manufacturing worldwide
5.1.2. Restraints
5.1.2.1. Availability of home remedies and other alternatives for acidity-related issues
5.1.3. Opportunities
5.1.3.1. Development of more instantly effective and long-lasting antacids
5.1.3.2. Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
5.1.4. Challenges
5.1.4.1. Drug recall and contamination issues associated with the antacids
5.2. Market Segmentation Analysis
5.2.1. Drug Class: Increasing preference for acid neutralizers for improved therapeutic action
5.2.2. Indication: Expanding need for antacids for the management of gastroesophageal reflux disease for reducing the acid’s ability to damage the esophageal lining.
5.2.3. Formulation: Rising preference for liquid antacid due to their already dissolved state, facilitating quicker relief from symptoms
5.2.4. Distribution Channel: Growing availability of antacids across retail pharmacies that provide instant access to antacids without the need for a prescription
5.3. Market Trend Analysis
5.3.1. Rising prevalence of gastroesophageal reflux disease across the Americas creating need for antacids
5.3.2. Government campaigns creating awareness for enhancing digestive health in the Asia-Pacific
5.3.3. Presence of well-established pharmaceutical industry and government support for domestic drug manufacturing in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Antacids Market, by Drug Class
6.1. Introduction
6.2. Acid Neutralizers
6.3. H2 Antagonist
6.4. Promotility Agents
6.5. Proton Pump Inhibitor
7. Antacids Market, by Formulation
7.1. Introduction
7.2. Liquid
7.3. Powder
7.4. Tablet
8. Antacids Market, by Indication
8.1. Introduction
8.2. Gastroesophageal Reflux Disease
8.3. Indigestion/Dyspepsia
8.4. Peptic Ulcer Disease
9. Antacids Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Americas Antacids Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Antacids Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Antacids Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
13.3.2. Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio
13.3.3. Camber Pharmaceuticals Launches Generic Wellbutrin SR
13.3.4. Reckitt Launches Gaviscon Double Action in Tamil Nadu, Helping People with Acidity and Heartburn
13.3.5. Wonderbelly Expands To Over 1,800 Target Stores to be Easily Accessible to a Broader Audience
13.3.6. Upsher-Smith Launches Famotidine For Oral Suspension
13.3.7. Zydus Secures Final Approval from the USFDA for its Esomeprazole Magnesium Product
13.3.8. Wonderbelly Antacid Brings Exclusive Flavor to Target With Launch
13.3.9. Marksans Pharma Gets USFDA Nod for Famotidine Tablets
13.3.10. ENO Expands its Portfolio with Two New Flavors, Jaljeera and Nimbu Masala